Company: APXIF
Filing Date: 2025-07-03
Form Type: F-4/A
Source: 0001213900-25-061545
Chunk: 145

Company: APx Acquisition Corp. I
Filing Date: 2025-07-03
Form: F-4/A
Chunk 145
---
 professionals will review and approve AI -drivenguidance as appropriate, specifically relating to medical diagnosis, and users will have access to human support if needed. However, there inherent risks to human oversight, which may be flawed or insufficient, potentially leading to errors in medical interpretation. Finally, the regulatory environment for AI in healthcare is evolving, with growing scrutiny around data privacy, transparency, and accountability. As our AI Agents process sensitive health data, we face risks related to compliance with diverse and emerging regulations. Failure to meet these standards, or any data breach resulting from either our own systems or third -partyinfrastructure, could lead to regulatory penalties, reputational damage, and financial losses. Additional Risks Related to the Business Combination SPAC has no operating or financial history and its results of operations and those of the Combined Company may differ significantly from the unaudited pro forma financial data included in this proxy statement. SPAC has no operating history and no revenues. This proxy statement/prospectus includes unaudited pro forma condensed combined statements of financial position and unaudited pro forma combined statements of operations for the year ended June 30, 2024 for OmnigenicsAI and SPAC. The unaudited pro forma combined statements of financial position as of June 30, 2024 combine the audited combined statements of financial position of OmnigenicsAI as of June 30, 2024, and the unaudited balance sheet of SPAC as of June 30, 2024 on a pro forma basis as if the Business Combination had been consummated on June 30, 2024. The unaudited pro forma combined statement of operations for the year ended June 30, 2024, combine the historical audited combined statement of operations of OmnigenicsAI for year ended June 30, 2024, and the historical statement of operations of SPAC for the twelve -monthperiod ended June 30, 2024 using its unaudited statement of operations for the six -monthperiod ended June 30, 2024 together with its audited statement of operations for the fiscal year ended December 31, 2023, deducting its unaudited statement of operations for the six -monthperiod ended June 30, 2023. The unaudited pro forma combined statement of operations were prepared on a pro forma basis as if the Business Combination had been consummated on July 1, 2023. The unaudited pro forma combined financial statements are presented